$59.2 Million is the total value of ARCH Venture Management, LLC's 5 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2020 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| RUBIUS THERAPEUTICS, INC. | 12 | Q3 2022 | 65.5% |
| ERASCA, INC. | 11 | Q2 2024 | 28.4% |
| VERVE THERAPEUTICS, INC. | 11 | Q2 2024 | 33.2% |
| SINGULAR GENOMICS SYSTEMS, INC. | 10 | Q1 2024 | 4.6% |
| EQRX, INC. | 8 | Q3 2023 | 52.4% |
| DENALI THERAPEUTICS, INC. | 8 | Q1 2024 | 28.6% |
| CHIASMA INC | 8 | Q3 2020 | 25.7% |
| UNITY BIOTECHNOLOGY, INC. | 8 | Q2 2024 | 2.1% |
| KURA ONCOLOGY INC | 7 | Q2 2020 | 27.6% |
| KARUNA THERAPEUTICS, INC. | 6 | Q1 2023 | 52.8% |
View ARCH Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-15 |
View ARCH Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.